^
    3ms
    OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • Oncolytic virus
    |
    BS001
    3ms
    OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer (clinicaltrials.gov)
    P2, N=45, Recruiting, Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial primary completion date • Oncolytic virus • Metastases
    |
    BS001
    8ms
    OH2 oncolytic virus: A novel approach to glioblastoma intervention through direct targeting of tumor cells and augmentation of anti-tumor immune responses. (PubMed, Cancer Lett)
    Significantly, these discoveries have driven the initiation of a phase I/II clinical trial (ClinicalTrials.gov: NCT05235074). This trial is designed to explore the potential of OH2 as a therapeutic option for patients with recurrent central nervous system tumors following surgical intervention.
    Journal • Oncolytic virus • IO biomarker • Tumor cell
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CD8 (cluster of differentiation 8) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CD4 (CD4 Molecule)
    |
    CDKN2A deletion • CDKN2A mutation
    |
    BS001
    over1year
    OH2 Administered by Intratumoral Injection (clinicaltrials.gov)
    P1, N=29, Not yet recruiting, Binhui Biopharmaceutical Co., Ltd.
    New P1 trial • Oncolytic virus • Metastases
    |
    BS001
    over1year
    OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • Oncolytic virus
    |
    BS001
    over1year
    OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients With Advanced Liver Cancer (clinicaltrials.gov)
    P1, N=12, Recruiting, Binhui Biopharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Feb 2023 --> May 2023
    Enrollment open • Trial initiation date • Oncolytic virus • Metastases
    |
    BS001
    over1year
    OH2 Injection in Melanoma (clinicaltrials.gov)
    P3, N=340, Recruiting, Binhui Biopharmaceutical Co., Ltd.
    New P3 trial
    |
    temozolomide • BS001
    over1year
    First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Binhui Biopharmaceutical Co., Ltd. | Initiation date: Mar 2023 --> Jun 2023
    Trial initiation date
    |
    Avastin (bevacizumab) • capecitabine • BS001
    over1year
    OH2 Injection in Solid Tumors (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Mar 2023 --> Mar 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    CSF2 (Colony stimulating factor 2)
    |
    Keytruda (pembrolizumab) • BS001
    almost2years
    OH2 Injection in Combination With HX008 for Melanoma. (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Nov 2022 --> Nov 2023 | Trial primary completion date: Nov 2022 --> Nov 2023
    Trial completion date • Trial primary completion date • Combination therapy
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    Puyouheng (pucotenlimab) • BS001
    over2years
    OH2 Oncolytic Viral Therapy in Solid Tumors (clinicaltrials.gov)
    P1/2, N=300, Recruiting, Wuhan Binhui Biotechnology Co., Ltd. | Trial completion date: Apr 2022 --> Apr 2023 | Trial primary completion date: Apr 2022 --> Apr 2023
    Trial completion date • Trial primary completion date • Oncolytic virus
    |
    CSF2 (Colony stimulating factor 2)
    |
    irinotecan • Puyouheng (pucotenlimab) • BS001
    over2years
    OH2 Injection in Solid Tumors (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Wuhan Binhui Biotechnology Co., Ltd. | Trial completion date: Mar 2022 --> Dec 2023 | Trial primary completion date: Mar 2022 --> Mar 2023
    Trial completion date • Trial primary completion date
    |
    CSF2 (Colony stimulating factor 2)
    |
    Keytruda (pembrolizumab) • BS001
    over3years
    OH2 Oncolytic Viral Therapy in Solid Tumors (clinicaltrials.gov)
    P1/2, N=300, Recruiting, Wuhan Binhui Biotechnology Co., Ltd. | Trial completion date: Dec 2020 --> Apr 2022 | Trial primary completion date: Dec 2020 --> Apr 2022
    Trial completion date • Trial primary completion date • Oncolytic virus
    |
    CSF2 (Colony stimulating factor 2)
    |
    irinotecan • Puyouheng (pucotenlimab) • BS001
    over3years
    OH2 Injection in Solid Tumors (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Wuhan Binhui Biotechnology Co., Ltd. | Trial completion date: Mar 2021 --> Mar 2022 | Trial primary completion date: Mar 2021 --> Mar 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    CSF2 (Colony stimulating factor 2)
    |
    Keytruda (pembrolizumab) • BS001
    4years
    OH2 Oncolytic Viral Therapy in Solid Tumors (clinicaltrials.gov)
    P1/2, N=300, Recruiting, Wuhan Binhui Biotechnology Co., Ltd. | Phase classification: P1 --> P1/2 | N=150 --> 300
    Phase classification • Enrollment change • Oncolytic virus
    |
    CSF2 (Colony stimulating factor 2)
    |
    irinotecan • Puyouheng (pucotenlimab) • BS001
    over4years
    OH2 Injection in Solid Tumors (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Wuhan Binhui Biotechnology Co., Ltd.
    Clinical • New P1/2 trial
    |
    CSF2 (Colony stimulating factor 2)
    |
    Keytruda (pembrolizumab) • BS001
    over4years
    [VIRTUAL] Safety and tolerability of intratumorally administered OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: A phase I dose escalation clinical study. (ASCO 2020)
    OH2 had a favorable safety profile with no DLTs and MTD. The dose expansion study in selected tumor types is currently underway. Research Funding: Wuhan Binhui Biotechnology Co., Ltd.
    Clinical • P1 data
    |
    CSF2 (Colony stimulating factor 2)
    |
    BS001